Search

Displaying results 3441 - 3450 of 7503 in total
  1. Drug

    XL999

    go.drugbank.com/drugs/DB05014
    Investigational

    XL999 has the potential to prevent tumor growth — both directly by a novel effect on tumor cell proliferation and indirectly through inhibition of the host angiogenic response. … XL999 induces a cell-cycle block by a mechanism distinct from those previously identified and exhibits broad antitumor activity in xenograft models.

  2. Drug

    Torcetrapib

    go.drugbank.com/drugs/DB06281
    Investigational

    Torcetrapib (CP-529414, Pfizer) was developed to treat hypercholesterolemia but its development was halted in 2006 when phase III studies showed excessive mortality in the treatment group receiving a combination

  3. Drug

    MF101

    go.drugbank.com/drugs/DB05052
    Investigational

    MF101 is a novel estrogen receptor beta (ERβ) selective agonist and unlike currently available hormone therapies, does not activate the estrogen receptor alpha (ERα), known to be implicated in tumor formation

  4. Drug

    Hu-rhEGF-rP64k/Mont

    go.drugbank.com/drugs/DB15781
    Investigational

    Hu-rhEGF-rP64k/Mont is a therapeutic vaccine composed by an antigen (recombinant human EGF (rhEGF) chemically conjugated to recombinant P64K (rP64K)) and an adjuvant (Montanide ISA51VG) being investigated … for the treatment of advanced non-small cell lung cancer (NSCLC).

  5. Drug

    SIG-007

    go.drugbank.com/drugs/DB17710
    Experimental

    Developed by Sigilon Therapeutics, t is being investigated for the treatment of Fabry Disease.[L46153] … SIG-007 is a gene therapy that consists of cells that are genetically modified with a non-viral vector to express human alpha-galactosidase A.

  6. Drug

    AZD 3355

    go.drugbank.com/drugs/DB05404
    Investigational

    It is developed by AstraZeneca and is currently in phase I/II trials.

  7. Drug

    Florbetapir F-18

    go.drugbank.com/drugs/DB09149
    ApprovedInvestigational

    Florbetapir (18F) is a radiopharmaceutical compound containing the radionuclide fluorine-18 bound to the compound florbetapir, a molecule that binds with high affinity to beta amyloid plaque, a peptide … The radionucleide fluorine-18 was chosen as it has a half life of 110 minutes allowing it to accumulate sufficiently in the brain before undergoing positon emission decay.

    Synonyms: 4-{(E)-2-[6-(2-{2-[2-(18F)fluoroethoxy]ethoxy}ethoxy)pyridin-3-yl]ethenyl}-N-methylaniline
  8. Drug

    Influenza B virus B/Michigan/01/2021 antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB16917
    Approved

    These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … The influenza vaccine, also known as the "flu shot", is a vaccine that helps to protect against infection from influenza viruses.

  9. Drug

    Ombitasvir

    go.drugbank.com/drugs/DB09296
    ApprovedInvestigational

    Ombitasvir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). … Lack of significant side effects and short duration of therapy is a considerable advantage over older interferon-based regimens, which were limited by infusion site reactions, reduced blood count, and

  10. Drug

    Mibefradil

    go.drugbank.com/drugs/DB01388
    ApprovedWithdrawn

    Mibefradil was withdrawn from the market in 1998 because of potentially harmful interactions with other drugs.